Navigation Links
GlycoFi and Dartmouth report full humanization of yeast glycosylation pathway in Science

For the first time, scientists have engineered yeast cells capable of producing a broad repertoire of recombinant therapeutic proteins with fully human sugar structures (glycosylation). These sugar structures ensure a glycoprotein's biological activity and half-life and to date, have necessitated the expression of therapeutic glycoproteins in mammalian hosts. The accomplishment reported today has the potential to eliminate the need for mammalian cell culture, while improving control over glycosylation, and improving performance characteristics of many therapeutic proteins.

Scientists from GlycoFi, Inc., a wholly owned subsidiary of Merck & Co., Inc., and their collaborators at Dartmouth-Hitchcock Medical Center published their report detailing the genetic engineering of the yeast Pichia pastoris to secrete human glycoproteins with fully complex, terminally sialyated N-glycans today in the September 8, 2006 issue of the journal Science. To demonstrate the utility of the engineered yeast strains, recombinant erythropoietin (Epo), a protein that stimulates the production of red blood cells, was expressed, purified and its activity demonstrated in vivo.

"Re-engineering the yeast glycosylation system to fully replicate the full repertoire of human glycosylation reactions has been a challenging six year effort that many doubted could be accomplished," said Tillman Gerngross, Ph.D., chief scientific officer of GlycoFi and professor of Bioengineering at Dartmouth College.

"This achievement required both the elimination of yeast-specific glycosylation reactions and the introduction of 14 heterologous genes, making this one of the most complex cellular engineering endeavors reported to date", said Stephen Hamilton, Ph.D., the lead author of the study and a senior scientist at GlycoFi.

Yeast offers numerous advantages as a recombinant protein expression system when compared to mammalian cell culture. These include the capability of producing higher recombinant protein titers, shorter fermentation times, and the ability to grow in chemically defined media, without risk of viral contamination from animal-derived ingredients.

"Switching to this technology will also provide improvements in product uniformity and overall production economics," Dr. Gerngross said. He noted that the GlycoFi and Dartmouth research team had previously published work showing how a panel of glyco-engineered yeast cell lines, displaying a more limited repertoire of human glycosylation reactions, had allowed the scientists to study the relationship between specific glycosylation structures on antibodies and their killing activity on cancer cells. Using this technology, the team had identified glycosylation structures that significantly improved an antibodies ability to kill cancer cells compared to the same antibody manufactured using mammalian cell culture.

"By engineering yeast to perform the final and, most complex step of human glycosylation, we are now able to conduct far more extensive structure-function investigations on a much wider range of therapeutic protein targets," Dr. Gerngross commented.
'"/>

Source:JKureczka@comcast.net


Related biology news :

1. GlycoFi announces the first production of antibodies with human glycosylation in yeast
2. Dartmouth study finds that arsenic inhibits DNA repair
3. Octopuses occasionally stroll around on two arms, UC Berkeley biologists report
4. Surprising findings reported about iron overload
5. Researchers report new pro-inflammatory role for anti-inflammatory enzyme
6. Biochemists report discovery of structure of major piece of telomerase; implications for cancer
7. Leprosy genome tells story of human migrations, French researchers report in Science
8. Novel live reporting system to track cells
9. Biased reporting found in cancer prognostic studies
10. New lead reported in tumor angiogenesis
11. Researchers report breakthrough against world’s deadliest viruses

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 23, 2017 , ... Bacterial biofilms, surface adherent communities ... cause diverse pathologies ranging from food poisoning and catheter infections to gum disease and ... the tens of billions of dollars per year, there is currently a paucity of ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... machine manufacturers to re-engineer their control technology again and again. METTLER TOLEDO has ... for machine manufacturers. The videos illustrate how integration of the ACT350 into Siemens ...
(Date:5/22/2017)... ... May 22, 2017 , ... Baltimore biotech firm, PathSensors, announced ... community in developing and issuing recommendations to grow Maryland's biohealth industry and position ... 2023. , The recommendations are contained in a report from ...
(Date:5/21/2017)... ... 19, 2017 , ... Ovation Fertility scientists’ work is being ... Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today and Saturday (May ... excellence in clinical laboratory services and regulations. , “We are pleased to ...
Breaking Biology Technology: